Alnylam Clinical Trials Finder
People Like You Power Progress Against Disease
We’re working every day to develop innovative new medicines for a broad range of rare and more common diseases. But we can’t do it alone. The process of developing new treatments relies on many groups of people, including, most importantly, those who participate in clinical trials.
We invite you to learn more about our current and prior clinical trials below, and about clinical research at Alnylam.
PATISIRAN (hATTR Amyloidosis)
TRIAL STATUS
COMPLETED
Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis
ALN-TTR02-002
LOCATION(S):
USA, Brazil, France, Germany, Portugal, Spain, Sweden, Portugal
FOR MORE INFO:
TRIAL STATUS
COMPLETED
The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
ALN-TTR02-003
LOCATION(S):
USA, Brazil, France, Germany, Portugal, Spain, Sweden
FOR MORE INFO:
TRIAL STATUS
COMPLETED
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
ALN-TTR02-004
LOCATION(S):
USA, Argentina, Australia, Brazil, Bulgaria, Canada, Cyprus, France, Germany, Italy, Japan, South Korea, Malaysia, Mexico, Netherlands, Portugal, Spain, Sweden, Taiwan, Turkey, United Kingdom
FOR MORE INFO:
TRIAL STATUS
ACTIVE, NOT RECRUITING
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
ALN-TTR02-006
LOCATION(S):
USA, Argentina, Australia, Brazil, Bulgaria, Canada, Cyprus, France, Germany, Italy, Japan, South Korea, Malaysia, Mexico, Netherlands, Portugal, Spain, Sweden, Taiwan, Turkey, United Kingdom
FOR MORE INFO:
TRIAL STATUS
COMPLETED
Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant
ALN-TTR02-008
LOCATION(S):
Italy, Sweden, Portugal, United Kingdom, Germany, Spain, France
FOR MORE INFO:
DOWNLOAD PLAIN LANGUAGE SUMMARY HERE:
TRIAL STATUS
RECRUITING
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
ALN-TTR02-010
LOCATION(S):
USA, Portugal, Italy, Spain, France, Germany, Netherlands
FOR MORE INFO:
TRIAL STATUS
ACTIVE, NOT RECRUITING
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
ALN-TTR02-011
LOCATION(S):
USA, Czechia, Denmark, Sweden, Argentina, Brazil, South Korea, Italy, Taiwan, United Kingdom, France, Japan, Hong Kong, Australia, Mexico, Bulgaria, Chile, Belgium, Netherlands, New Zealand
FOR MORE INFO:
TRIAL STATUS
COMPLETED
A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation
ALN-TTR02-012
LOCATION(S):
USA
FOR MORE INFO:
TRIAL STATUS
RECRUITING
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
ALN-TTR02-013
LOCATION(S):
USA, Portugal, France, Israel, Italy, Netherlands, Spain, Denmark, Germany
FOR MORE INFO:
GIVOSIRAN (Acute Hepatic Porphyria)
TRIAL STATUS
COMPLETED
A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)
ALN-AS1-001
LOCATION(S):
USA, Sweden, United Kingdom
FOR MORE INFO:
TRIAL STATUS
COMPLETED
A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)
ALN-AS1-002
LOCATION(S):
USA, Sweden, United Kingdom
FOR MORE INFO:
DOWNLOAD PLAIN LANGUAGE SUMMARY HERE:
TRIAL STATUS
COMPLETED
ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
ALN-AS1-003
LOCATION(S):
USA, Australia, Bulgaria, Canada, Denmark, Finland, France, Germany, Italy, Japan, South Korea, Mexico, Netherlands, Poland, Spain, Sweden, Taiwan, United Kingdom
FOR MORE INFO:
DOWNLOAD PLAIN LANGUAGE SUMMARY HERE:
TRIAL STATUS
RECRUITING
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
ALN-AS1-006
LOCATION(S):
USA, France, Germany, Italy, United Kingdom
FOR MORE INFO:
TRIAL STATUS
COMPLETED
EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
ALN-AS1-NT-001
LOCATION(S):
USA, Australia, Belgium, Bulgaria, Czechia, Finland, France, Germany, Italy, Israel, Mexico, Netherlands, Norway, Poland, South Africa, South Korea, Spain, Switzerland, Taiwan, United Kingdom
FOR MORE INFO:
INCLISIRAN (Hypercholesterolemia)
TRIAL STATUS
COMPLETED
A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
ALN-PCSSC-001
LOCATION(S):
United Kingdom
FOR MORE INFO:
LUMASIRAN (Primary Hyperoxaluria)
TRIAL STATUS
COMPLETED
Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1
ALN-GO1-001
LOCATION(S):
USA, United Kingdom, Germany, Israel, Netherlands
FOR MORE INFO:
TRIAL STATUS
ACTIVE, NOT RECRUITING
An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Patients With Primary Hyperoxaluria Type 1
ALN-GO1-002
LOCATION(S):
France, Germany, Netherlands, United Kingdom, Israel
FOR MORE INFO:
DOWNLOAD PLAIN LANGUAGE SUMMARY HERE:
TRIAL STATUS
ACTIVE, NOT RECRUITING
A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 (ILLUMINATE-A)
ALN-GO1-003
LOCATION(S):
USA, United Kingdom, France, Germany, Netherlands, Switzerland, Israel, UAE
FOR MORE INFO:
DOWNLOAD PLAIN LANGUAGE SUMMARY HERE:
TRIAL STATUS
ACTIVE, NOT RECRUITING
A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 (ILLUMINATE-B)
ALN-GO1-004
LOCATION(S):
USA, United Kingdom, France, Germany, Israel
FOR MORE INFO:
DOWNLOAD PLAIN LANGUAGE SUMMARY HERE:
TRIAL STATUS
ACTIVE, NOT RECRUITING
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (ILLUMINATE-C)
ALN-GO1-005
LOCATION(S):
Israel, USA, France, Belgium, United Arab Emirates(UAE), Netherlands, Turkey, Australia, Jordan, Lebanon, United Kingdom, Italy
FOR MORE INFO:
TRIAL STATUS
RECRUITING
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
ALN-GO1-007
LOCATION(S):
USA, Belgium
FOR MORE INFO:
TRIAL STATUS
RECRUITING
A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
ALN-GO1-008
LOCATION(S):
USA, Italy
FOR MORE INFO:
CEMDISIRAN (Complement-Mediated Diseases)
TRIAL STATUS
COMPLETED
A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH
ALN-CC5-001
LOCATION(S):
Spain, United Kingdom
FOR MORE INFO:
TRIAL STATUS
ACTIVE, NOT RECRUITING
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
ALN-CC5-005
LOCATION(S):
Canada, Philippines, Spain, Sweden, United Kingdom, Singapore, France, Malaysia, Taiwan
FOR MORE INFO:
VUTRISIRAN (ATTR Amyloidosis)
TRIAL STATUS
ACTIVE, NOT RECRUITING
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
ALN-TTRSC02-002
LOCATION(S):
USA, Argentina, Bulgaria, France, Portugal, Malaysia, Cyprus, Germany, Japan, South Korea, Greece, Sweden, United Kingdom, Taiwan, Belgium, Mexico, Italy, Australia, Canada, Netherlands, Spain, Brazil
FOR MORE INFO:
DOWNLOAD PLAIN LANGUAGE SUMMARY HERE:
TRIAL STATUS
ACTIVE, NOT RECRUITING
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
ALN-TTRSC02-003
LOCATION(S):
USA, Latvia, Spain, France, Sweden, Lithuania, Portugal, Australia, Republic of Korea, Germany, Norway, United Kingdom, Israel, Hungary, Denmark, Ireland, Canada, Moldova, Austria, Poland, Netherlands, Belgium, Croatia, Peru, Argentina, Japan, Malaysia, Thailand, Colombia, Czechia
FOR MORE INFO:
ALN-AAT02 (Alpha-1 Liver Disease)
TRIAL STATUS
TERMINATED
A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
ALN-AAT02-001
LOCATION(S):
United Kingdom
FOR MORE INFO:
ZILEBESIRAN (Hypertension)
TRIAL STATUS
ACTIVE, NOT RECRUITING
A Study to Evaluate ALN-AGT01 in Patients With Hypertension
ALN-AGT01-001
LOCATION(S):
United Kingdom
FOR MORE INFO:
TRIAL STATUS
RECRUITING
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1)
ALN-AGT01-002
LOCATION(S):
USA, Canada, Ukraine, Puerto Rico, United Kingdom
FOR MORE INFO:
TRIAL STATUS
RECRUITING
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
ALN-AGT01-003
LOCATION(S):
USA, Canada, Estonia, Poland, United Kingdom, Latvia, Lithuania
FOR MORE INFO:
ALN-LEC (LECT2 Amyloidosis)
TRIAL STATUS
TERMINATED
A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease
ALN-LECT2-NT-001
LOCATION(S):
USA, United Kingdom, India, Malaysia, Mexico, Egypt
FOR MORE INFO:
ALN-APP (Alzheimer’s Disease & Cerebral Amyloid Angiopathy)
TRIAL STATUS
RECRUITING
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
ALN-APP-001
LOCATION(S):
Canada, USA, Netherlands and UK
FOR MORE INFO:
ALN-XDH (Gout)
TRIAL STATUS
RECRUITING
A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout
ALN-XDH-001
LOCATION(S):
United Kingdom
FOR MORE INFO:
Alnylam provides lay summaries as part of our commitment to transparency and ensuring our clinical trial information is accessible to patients, health care providers, researchers and the general public. These summaries represent the results from individual studies and may not represent all of the information about the therapy studied; other studies may have different results. Plain language summaries are not intended for promotional purposes or indication, to guide treatment decisions, or to replace the advice of a healthcare professional. You should not change your therapy based on the results of these studies. Always consult with your health care provider about your treatment options and any questions you may have.